The family of resistin-like molecules (RELMs) consists of four members in rodents (RELMα/FIZZ1/HIMF, RELMβ/FIZZ2, Resistin/FIZZ3, and RELMγ/FIZZ4) and two members in humans (Resistin and RELMβ), all of which exhibit inflammation-regulating, chemokine, and growth factor properties. The importance of these cytokines in many aspects of physiology and pathophysiology, especially in cardiothoracic diseases, is rapidly evolving in the literature. In this review article, we attempt to summarize the contribution of RELM signaling to the initiation and progression of lung diseases, such as pulmonary hypertension, asthma/allergic airway inflammation, chronic obstructive pulmonary disease, fibrosis, cancers, infection, and other acute lung injuries. The potential of RELMs to be used as biomarkers or risk predictors of these diseases also will be discussed. Better understanding of RELM signaling in the pathogenesis of pulmonary diseases may offer novel targets or approaches for the development of therapeutics to treat or prevent a variety of inflammation, tissue remodeling, and fibrosis-related disorders in respiratory, cardiovascular, and other systems.

中文翻译：

---

肺病中的抵抗素家族蛋白。

抵抗素样分子 (RELM) 家族由啮齿动物的四个成员（RELMα/FIZZ1/HIMF、RELMβ/FIZZ2、抵抗素/FIZZ3 和 RELMγ/FIZZ4）和人类的两个成员（抵抗素和 RELMβ）组成，所有这些表现出炎症调节、趋化因子和生长因子特性。这些细胞因子在生理学和病理生理学的许多方面的重要性，特别是在心胸疾病中，在文献中正在迅速发展。在这篇综述文章中，我们试图总结 RELM 信号对肺部疾病的发生和进展的贡献，如肺动脉高压、哮喘/过敏性气道炎症、慢性阻塞性肺病、纤维化、癌症、感染和其他急性肺损伤. 还将讨论 RELM 用作这些疾病的生物标志物或风险预测因子的潜力。